We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Urine Tests Could Reveal Early Signs of Cancer and Other Diseases

By LabMedica International staff writers
Posted on 24 Oct 2024

Early detection is essential for effectively treating diseases such as cancer, yet not everyone has convenient access to screening tools. More...

For issues affecting the genitourinary (GU) tract, which includes the kidneys, prostate, and bladder, healthcare providers typically employ a combination of screening methods, including blood tests, imaging, and physical examinations. Researchers are now developing an even simpler tool for early disease screening—urine analysis.

A new study by a team of scientists, including researchers from the University of Texas at Arlington (UTA; Arlington, TX, USA), has shown that analyzing RNA (a type of genetic material) and other substances present in urine can indicate changes in cell types, potentially revealing early signs of cancer and other diseases. This approach could assist clinicians in identifying issues earlier when they are more easily treatable without requiring invasive procedures. In the study, the researchers collected urine samples from two groups: healthy individuals and those with kidney stones. They extracted two types of RNA from the urine—cell-free RNA, which is suspended freely in the urine, and sediment RNA, derived from solid particles. The RNA types were sequenced and analyzed, comparing samples from healthy individuals with those from patients who had kidney stones.

The findings of the study were published in Clinical Chemistry, a journal of the Association for Diagnostics & Laboratory Medicine (ADLM), revealing that advanced urine analyses could identify cellular patterns that indicate the presence of disease. The next phase of the research focuses on employing advanced machine learning techniques to further refine the differences detectable when comparing the RNA and protein signatures of healthy individuals to those diagnosed with diseases. The researchers aim to identify additional biomarkers that could facilitate the development of simpler, less invasive diagnostic methods in the future.

“We’re excited about this new research as it may lead to new, easier screening tools that can help detect diseases of the bladder, kidneys, and prostate,” said Joseph Buonomo, assistant professor of chemistry at UTA and an author of the study. “Although our patient cohort was small, it lays the groundwork for development of a type of ‘non-invasive liquid biopsy’ that will be used to track the progression of ailments like kidney stones, diabetes, and cancer using urine instead of surgical specimens.” 

Related Links:
University of Texas at Arlington


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.